Last updated: August 17, 2026

Stem cell transplantation has emerged as a promising strategy to treat a variety of diseases, including hematologic malignancies. However, graft-versus-host disease (GvHD) remains a major complication associated with stem cell transplantation. GvHD occurs when donor immune cells attack the recipient’s healthy tissues, leading to inflammation and organ damage.
Stem Cell Transplantation: A Promising Strategy

Stem cell transplantation involves the transfer of healthy stem cells from a donor to a recipient. These stem cells can differentiate into various cell types, including immune cells, which can help to restore the recipient’s immune system. Stem cell transplantation has been used to successfully treat a variety of hematologic malignancies, including leukemia, lymphoma, and myeloma.
Immunomodulatory Potential of Stem Cells

Stem cells have immunomodulatory properties that can help to prevent or treat GvHD. These properties include the ability to:

  1. Suppress the activation of donor immune cells: Stem cells can release factors that inhibit the activation of donor immune cells, thereby reducing the risk of GvHD.
  2. Promote the development of regulatory immune cells: Stem cells can promote the development of regulatory immune cells, which help to control the immune response and prevent excessive inflammation.

Stem cell-based approaches hold great promise for overcoming GvHD and improving the outcomes of stem cell transplantation. Further research is needed to develop and refine these approaches, but they have the potential to revolutionize the treatment of hematologic malignancies.

Scientific Evidence

Research in stem cells and cellular technologies continues to develop across regenerative medicine, immunology and tissue repair. The strength of evidence differs considerably between cell types, medical conditions and treatment protocols. Laboratory findings, early clinical studies and established therapeutic applications should therefore be evaluated separately. Any clinical decision should be based on the patient’s diagnosis, current medical status, available evidence and the regulatory framework applicable in the country of treatment.

Extracellular Vesicles and Exosomes

Extracellular vesicles, including populations commonly described as exosomes, are being investigated as mediators of intercellular communication and paracrine activity. Their biological properties depend on the source cells, isolation method, characterization, concentration and storage conditions. Measurements expressed only as particle numbers do not provide a complete assessment of identity, purity or potency. Clinical claims should therefore be distinguished carefully from laboratory research and early-stage clinical evidence.

Extracellular Vesicles and Exosomes

Extracellular vesicles, including populations commonly described as exosomes, are being investigated as mediators of intercellular communication and paracrine activity. Their biological properties depend on the source cells, isolation method, characterization, concentration and storage conditions. Measurements expressed only as particle numbers do not provide a complete assessment of identity, purity or potency. Clinical claims should therefore be distinguished carefully from laboratory research and early-stage clinical evidence.

Scientific case review

Scientific Case Review

Would you like to understand whether current clinical programs, recent research developments, or emerging approaches may be relevant to your individual situation?

Share your question with our scientific research team and receive information focused on the areas of current research that may be relevant to your case.

  • Review of the information you provide
  • Relevant research and clinical program information
  • A clear response focused on your situation
What happens next? Send your question, receive a focused scientific review, and get a clear response about research and clinical programs relevant to your situation.
Your scientific review will be prepared by Dr. Helen Melnik, PhD , who has more than 25 years of experience in stem cell research and international clinical programs.

No obligation. Your question will be reviewed confidentially.

Educational and research information only. This service does not constitute medical advice, diagnosis, prescription, or a personalized treatment recommendation.

Categories:   Chronic Bronchitis  StrokeStem Cell Marketstem cell therapiesStem Cell therapyStem Cell Therapy & Clinical ResearchStem Cells Clinical Trialsstem cells therapyStem cells therapy of cerebral palsystem cells treatmentstem cells treatment in ukrainestem cells warningsurgery

NBScience

contract research organization

WhatsApp